000			03503cam a2200349 a 4500
003			EG-GiCUC
005			20250223031848.0
008			171127s2017 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.09.M.Sc.2017.Os.C
100	0		_aOsama Kamel Mohamed Noreldeen
245	1	0	_aComparison of the clinical outcome of methicillin resistant staphylococcus aureus (MRSA) pneumonia treated with linezolid versus vancomycin in The Critical Care Department of Cairo University from 2012 to 2014 : _bRetrospective study / _cOsama Kamel Mohamed Noreldeen ; Supervised Waheed Radwan , Sally Salah Eldine , Abdelraoof Fahmy
246	1	5	_aمقارنه الناتج الاكلينيكى لعلاج بكتريا المكورات العنقودية (مرسا) مسببة الالتهاب الرئوى بعقار اللينزوليد مقارنه بعقار الفانكومايسن فى قسم طب الحالات الحرجة بجامعة القاهرة فى الفترة من عام 2012 الى عام 2014 : _bدراسة تراجعية الزمن
260			_aCairo : _bOsama Kamel Mohamed Noreldeen , _c2017
300			_a122 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Critical Care Medicine
520			_aAim: The objective of this study is to review the local management of patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia treated with vancomycin or linezolid with the goal to define if any difference exists among these antimicrobials in regard to clinical and economic outcomes. Patients and methods: All ICU patients in Kasr Eleiny hospital from 2012 to 2014 who developed hospital acquired pneumonia and treated with vancomycin or linezolid were enrolled in the study if they fulfill the following criteria: Clinical criteria for HAP/VAP. Isolation of MRSA from a respiratory sample or blood culture within 48 hours of the diagnosis of HAP/VAP. Treatment of MRSA HAP/ VAP with either vancomycin or linezolid. Patients{u2019} not meeting enrollment criteria had been excluded. Results: The study groups were 30 patients, 50 % were males and 50% were females. Patients who received vancomycin were 17 patients and patients who received linezolid included 13 patients. At onset of diagnosis SOFA score was significantly higher in linezolid group which was 10.1±2.84 compared to 6.70±3.15 in vancomycin group with P value 0.003. Expected mortality was significantly higher in linezolid group which was 61.5/% for expected mortality 15-20% and 30.8% for expected mortality 40-50%, vs 29.4% and 5.9% in vancomycin group with P value 0.008. At the end of the antibiotic course there was no significant difference between both groups regarding scoring severity and expected mortality. Successful weaning from mechanical ventilation was significantly higher in the group receiving linezolid compared to the group receiving vancomycin 61.5% versus 17.6%
530			_aIssued also as CD
653		4	_aLinezolid versus vancomycin
653		4	_aMethicillin Resistant Staphylococcus Aureus (MRSA)
653		4	_aMRSA
700	0		_aAbdelraoof Fahmy , _eSupervisor
700	0		_aSally Salah Eldine , _eSupervisor
700	0		_aWaheed Radwan , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c63709 _d63709